Article
Cell Biology
Paola Spitalieri, Federica Centofanti, Michela Murdocca, Maria Giovanna Scioli, Andrea Latini, Silvia Di Cesare, Gennaro Citro, Antonio Rossi, Augusto Orlandi, Shane Miersch, Sachdev S. Sidhu, Pier Paolo Pandolfi, Annalisa Botta, Federica Sangiuolo, Giuseppe Novelli
Summary: In this study, a new tetravalent neutralizing antibody and a synthetic peptide were tested on human cells for the first time, showing potential as immunotherapeutic candidates for COVID-19. The findings indicate that both approaches significantly reduce viral entry and affect the expression of genes related to innate immunity and inflammatory response.
Article
Multidisciplinary Sciences
Yannic C. Bartsch, Deniz Cizmeci, Jaewon Kang, Hailong Gao, Wei Shi, Abishek Chandrashekar, Ai-ris Y. Collier, Bing Chen, Dan H. Barouch, Galit Alter
Summary: The omicron (B.1.1.529) BA.1 variant has mutations that evade vaccine immunity, but severe disease is still relatively low due to T cell recognition and non-neutralizing antibodies. However, the BA.2 sublineage, which is more transmissible, may evade some vaccine-induced responses. This study found that vaccine-induced immune responses were compromised against both omicron sublineages, but non-neutralizing Fc effector functions were attenuated more in BA.2 compared to BA.1.
Article
Biochemistry & Molecular Biology
Zhenhua Yu, Ayesha Sohail, Alessandro Nutini, Robia Arif
Summary: The ongoing threat posed by Coronavirus is analyzed through mathematical modeling, hypothesizing transmission rates and considering time delay factors. The research aims to enhance understanding and response to the current pandemic threat.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Abdolreza Esmaeilzadeh, Samaneh Rostami, Pegah M. Yeganeh, Safa Tahmasebi, Majid Ahmadi
Summary: The emergence of the new SARS-CoV-2 virus causing COVID-19 has led to a global health crisis, with antibody-based therapies showing promising outcomes in accelerating treatment, preventing viral spread, and managing the pandemic.
JOURNAL OF CELLULAR BIOCHEMISTRY
(2021)
Article
Medicine, General & Internal
Rachel A. Bender Ignacio, Kara W. Chew, Carlee Moser, Judith S. Currier, Joseph J. Eron, Arzhang Cyrus Javan, Mark J. Giganti, Evgenia Aga, Michael Gibbs, Herve Tchouakam Kouekam, Eva Johnsson, Mark T. Esser, Keila Hoover, Gene Neytman, Matthew Newell, Eric S. Daar, William Fischer, Courtney V. Fletcher, Jonathan Z. Li, Alexander L. Greninger, Robert W. Coombs, Michael D. Hughes, Davey Smith, David Alain Wohl
Summary: These two clinical trials showed that tixagevimab and cilgavimab monoclonal antibodies were safe and effective for treating early COVID-19, but did not change the time to symptom improvement. The treatment outcomes were better for the intramuscular injection.
Review
Infectious Diseases
Jiawen Deng, Kiyan Heybati, Harikrishnaa Ba Ramaraju, Fangwen Zhou, Daniel Rayner, Shayan Heybati
Summary: This study assessed and compared the efficacy and safety of different anti-SARS-CoV-2 antibody regimens for COVID-19 through a systematic review and meta-analysis. The results showed that certain antibody regimens can significantly reduce mortality and hospitalization rates, but convalescent plasma and anti-COVID IVIg were not effective and may increase the odds of adverse events. Future research should further examine the impact of baseline seronegativity, disease severity, patient risk factors, and viral strain variation on the efficacy of these regimens.
Article
Microbiology
Yinjuan Li, Lu Qi, Haihong Bai, Chunyun Sun, Shuping Xu, Yu Wang, Chunyu Han, Yan Li, Long Liu, Xiaoqiang Cheng, Ju Liu, Chunpu Lei, Yuanxu Tong, Mingli Sun, Lixin Yan, Weiqiu Chen, Xisheng Liu, Qing Liu, Liangzhi Xie, Xinghe Wang
Summary: The study demonstrated that SCTA01 had promising prophylactic and therapeutic potential for COVID-19 in healthy adults, with a safe and well-tolerated dose range of 5 to 50 mg/kg. The PK parameters of SCTA01 showed nearly linear dose-proportional increases, and most adverse events were mild.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Chemistry, Medicinal
Guitti Pourdowlat, Fatemeh Saghafi, Abolfazl Mozafari, Adeleh Sahebnasagh, Atefeh Abedini, Mohsen Nabi Meybodi, Ali Salehi Nezamabadi, Seyed Ruhollah Mousavinasab, Arda Kiani, Hanieh Raji, Nadia Soltani, Mehdi Gholmzadeh Baeis, Esmaeil Eidani, Abdolrahim Sadeghi Yakhdani, Fatemeh Movaseghi, Solomon Habtemariam, Zohreh Akhoundi Meybodi, Mohsen Gholinataj Jelodar
Summary: Colchicine has shown clinical benefits in the management of COVID-19 through its anti-inflammatory effect. It can improve clinical outcomes and reduce pulmonary infiltration in COVID-19 patients.
PHYTOTHERAPY RESEARCH
(2022)
Article
Multidisciplinary Sciences
Jeremy Dahmen, Arjan Vermeulen, Sophie Payne, Casey Lippmeier
Summary: The emergence of COVID-19 has highlighted the limitations of research and development pipelines and scaled manufacturing. Existing vaccines and treatments are constrained by production scales and cost, hindering global deployment. Therefore, there is a pressing need to produce cost-effective interventions at larger scales in a shorter time while maintaining high quality.
Article
Oncology
Binghe Xu, Qingyuan Zhang, Tao Sun, Wei Li, Yue'e Teng, Xichun Hu, Igor Bondarenko, Hryhoriy Adamchuk, Liangming Zhang, Dmytro Trukhin, Shusen Wang, Hong Zheng, Zhongsheng Tong, Yaroslav Shparyk, Qingyu Wang
Summary: HLX02, an approved biosimilar of trastuzumab, showed equivalent efficacy, safety, and immunogenicity compared with reference trastuzumab in patients with HER2-positive recurrent or metastatic breast cancer. The study concluded that HLX02 is a reliable alternative to trastuzumab for these patients.
Review
Biotechnology & Applied Microbiology
Frances Rocamora, Angelo G. Peralta, Seunghyeon Shin, James Sorrentino, Mina Ying Min Wu, Eric A. Toth, Thomas R. Fuerst, Nathan E. Lewis
Summary: Glycosylation, a critical quality attribute, significantly influences the physical properties, safety profile, and biological activity of therapeutic proteins. Optimizing protein glycosylation is important for developing more effective therapies.
BIOTECHNOLOGY ADVANCES
(2023)
Article
Immunology
Basudev Paudyal, Adam McNee, Pramila Rijal, B. Veronica Carr, Alejandro Nunez, John McCauley, Rodney S. Daniels, Alain R. Townsend, John A. Hammond, Elma Tchilian
Summary: Prophylactic intravenous administration of specific monoclonal antibodies in pigs showed significant reduction in lung pathology and virus loads, but not consistent reduction in nasal shedding. The effect on lung pathology and virus load is consistent across different doses, suggesting that lower doses may be effective in reducing disease severity.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Pharmacology & Pharmacy
Shanshan Li, Xiaojie Wu, Nanyang Li, Guoying Cao, Jingjing Wang, Yuancheng Chen, Size Li, Jinjie He, Jufang Wu, Haijing Yang, Ke Lin, Chao Qiu, Angela Liu, He Zhou, Francisco Adrian, Liang Schweizer, Wenhong Zhang, Jingwen Gu, Jing Zhang
Summary: The aim of this study was to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of HFB30132A in healthy Chinese adults. Results showed that HFB30132A was safe and generally well-tolerated after single IV doses of 1,000 mg or 2,000 mg, and did not induce an immunogenic response. The findings support further clinical development of HFB30132A.
FRONTIERS IN PHARMACOLOGY
(2023)
Editorial Material
Immunology
Nobunao Ikewaki, Gene Kurosawa, Gary A. Levy, Senthilkumar Preethy, Samuel J. K. Abraham
Summary: A potential risk of COVID-19 vaccines is antibody-dependent disease enhancement (ADE), where vaccine-induced antibodies may enhance SARS-CoV-2 acquisition or increase disease severity. ADE is thought to occur through abnormal macrophages induced by the vaccine response or excessive antibody effector functions. Beta-glucans, natural polysaccharides known for immunomodulation, are suggested as safer vaccine adjuvants for COVID-19. They interact with macrophages, elicit beneficial immune responses, and enhance the immune system without over-activation.
Review
Pharmacology & Pharmacy
Behnam Amani, Bahman Amani
Summary: This study evaluated the efficacy and safety of regdanvimab, an anti-SARS-COV-2 monoclonal antibody, for the treatment of confirmed COVID-19. Eight studies involving 4793 patients were included, showing significant differences in terms of hospital stay, clinical recovery, disease progression, oxygen therapy need, and duration. However, no significant differences were found in mortality rate, mechanical ventilation need, and hospital admission rate. The incidence of adverse events was similar in both groups. Further research is needed to confirm these findings.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Urology & Nephrology
Daniele Amparore, Federico Piramide, Sabrina De Cillis, Paolo Verri, Alberto Piana, Angela Pecoraro, Mariano Burgio, Matteo Manfredi, Umberto Carbonara, Michele Marchioni, Riccardo Campi, Cristian Fiori, Enrico Checcucci, Francesco Porpiglia
Summary: The use of 3D virtual models in robot-assisted partial nephrectomy (RAPN) has shown promising results in surgical planning and indication, intraoperative navigation, and surgical training. However, further research and development are needed, and the potential role of artificial intelligence in improving 3D virtual modeling technology in RAPN should be explored.
WORLD JOURNAL OF UROLOGY
(2022)
Review
Medicine, General & Internal
Eduard Roussel, Riccardo Campi, Daniele Amparore, Riccardo Bertolo, Umberto Carbonara, Selcuk Erdem, Alexandre Ingels, Onder Kara, Laura Marandino, Michele Marchioni, Stijn Muselaers, Nicola Pavan, Angela Pecoraro, Benoit Beuselinck, Ivan Pedrosa, David Fetzer, Maarten Albersen
Summary: The incidental detection of renal masses has increased in recent years, resulting in the need for better presurgical characterization of these masses. Novel ultrasound-based techniques, such as contrast-enhanced ultrasound, ultrasound molecular imaging, elastography, and micro-Doppler imaging, have shown potential in non-invasively characterizing renal masses, but further validation and research are needed.
JOURNAL OF CLINICAL MEDICINE
(2022)
Correction
Urology & Nephrology
Maria Carmen Mir, Michele Marchionic, Homi Zargard, K. Zargar-Shoshtari, A. S. Fairey, Laura S. Mertens, C. P. Dinney, L. M. Krabbei, M. S. Cookson, N. E. Jacobsen, J. Griffin, J. S. Montgomery, N. Vasdev, E. Y. Yu, E. Xylinas, J. S. McGrathr, W. Kassoufs, M. A. Dall'Era, S. S. Sridhar, J. Aningn, S. F. Shariat, J. L. Wright, A. C. Thorpe, T. M. Morganm, J. M. Holzbeierlein, T. J. Bivalacquax, S. North, D. A. Barocas, Y. Lotan, P. Grivaso, A. J. Stephenson, J. B. Shah, B. W. van Rhijng, P. E. Spiess, S. Daneshmand, P. C. Blackd
EUROPEAN UROLOGY FOCUS
(2022)
Review
Medicine, General & Internal
Daniela Fasanella, Alessio Antonaci, Francesco Esperto, Roberto M. Scarpa, Matteo Ferro, Luigi Schips, Michele Marchioni
Summary: Several studies have explored the potential of specific miRNAs in predicting RCC recurrence, showing varying levels of accuracy and significant associations with survival outcomes. However, further research is needed to determine the efficacy of miRNA-based prognostic markers for routine clinical use.
Review
Urology & Nephrology
Alexandre Ingels, Riccardo Campi, Umberto Capitanio, Daniele Amparore, Riccardo Bertolo, Umberto Carbonara, Selcuk Erdem, Onder Kara, Tobias Klatte, Maximilian C. Kriegmair, Michele Marchioni, Maria C. Mir, Idir Ouzaid, Nicola Pavan, Angela Pecoraro, Eduard Roussel, Alexandre de la Taille
Summary: The standard treatment for renal cell carcinoma relies on surgery for low-risk localized tumors and systemic treatment for poor-prognosis metastatic disease. However, there is a grey area for the treatment of high-risk localized tumors and metastatic disease with a good-to-intermediate prognosis. Recent practice-changing trials have transformed the therapeutic options for metastatic renal cell carcinoma. Treatments targeting vascular endothelial growth factor have been the mainstay, but immune checkpoint inhibitors have revolutionized the treatment landscape. The potential benefits of these therapies in the neoadjuvant and adjuvant settings have been investigated. The role of surgery for metastatic disease has been redefined, and there is growing interest in deferred surgery for residual tumors or metastases after checkpoint inhibitor treatment.
NATURE REVIEWS UROLOGY
(2022)
Review
Medicine, General & Internal
Stijn Muselaers, Selcuk Erdem, Riccardo Bertolo, Alexandre Ingels, Onder Kara, Nicola Pavan, Eduard Roussel, Angela Pecoraro, Michele Marchioni, Umberto Carbonara, Laura Marandino, Daniele Amparore, Riccardo Campi
Summary: PSMA PET/Computed Tomography has the potential to be an important imaging tool for staging and monitoring renal cell carcinoma, as it is highly expressed in the microvasculature of solid tumors.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Matteo Ferro, Octavian Sabin Tataru, Gennaro Musi, Giuseppe Lucarelli, Abdal Rahman Abu Farhan, Francesco Cantiello, Rocco Damiano, Rodolfo Hurle, Roberto Contieri, Gian Maria Busetto, Giuseppe Carrieri, Luigi Cormio, Francesco Del Giudice, Alessandro Sciarra, Sisto Perdona, Marco Borghesi, Carlo Terrone, Evelina La Civita, Pierluigi Bove, Riccardo Autorino, Matteo Muto, Nicolae Crisan, Michele Marchioni, Luigi Schips, Francesco Soria, Daniela Terracciano, Rocco Papalia, Felice Crocetto, Biagio Barone, Giorgio Ivan Russo, Stefano Luzzago, Giuseppe Mario Ludovico, Mihai Dorin Vartolomei, Francesco Alessandro Mistretta, Vincenzo Mirone, Ottavio de Cobelli
Summary: This study aimed to investigate the predictive power of the systemic inflammatory marker mGPS in predicting oncological outcomes in HG/G3 T1 NMIBC patients. The study found that mGPS was associated with recurrence but had no statistical significance in progression. The results showed significant differences in survival rates among patients in different mGPS subgroups.
Article
Immunology
Ucciferri Claudio, Auricchio Antonio, Reale Marcella, Costantini Erica, Vecchiet Jacopo, Falasca Katia
Summary: This study aimed to assess plasma inflammatory biomarkers in relation to multiple cardiovascular risk scores in HIV patients. The results showed a strong correlation between selected inflammatory biomarkers and cardiovascular risk scores, suggesting their potential as reliable predictors of cardiovascular disease in this population. Routine use of these biomarkers could be a valuable tool for clinicians to monitor cardiovascular risk in HIV patients.
CURRENT HIV RESEARCH
(2022)
Review
Medicine, General & Internal
Octavian Sabin Tataru, Michele Marchioni, Felice Crocetto, Biagio Barone, Giuseppe Lucarelli, Francesco Del Giudice, Gian Maria Busetto, Alessandro Veccia, Arturo Lo Giudice, Giorgio Ivan Russo, Stefano Luzzago, Mattia Luca Piccinelli, Mihai Dorin Vartolomei, Gennaro Musi, Matteo Ferro
Summary: The development of novel molecular imaging techniques for preoperative diagnosis of renal cell carcinoma can help reduce postoperative renal function loss and complications. We reviewed the research on SPECT/CT and PET-CT molecular imaging, which showed promising results in distinguishing between benign and malignant lesions, as well as different subtypes of clear cell renal cell carcinoma. Nuclear medicine has played a vital role in evaluating primary and secondary lesions and has recently shown potential with new radiotracers in renal carcinoma diagnosis. Further research is needed to validate these findings and implement these diagnostic techniques in precision medicine.
Article
Biochemistry & Molecular Biology
Michele Sallese, Konstantinos Efthymakis, Michele Marchioni, Benedetto Neri, Beatrice Dufrusine, Enrico Dainese, Marta Di Nicola, Matteo Neri
Summary: Coeliac disease (CeD) is an immune-mediated disorder triggered by gluten, involving autoimmune damage to the intestines and other systems. The Th1 inflammatory response and innate immune response play important roles in its pathogenesis. Gene expression analysis found key cytokines and immune pathways involved. Comparison with non-celiac gluten sensitivity (NCGS) revealed molecular overlap, suggesting a common root (dysregulated long non-coding RNAs) for these diseases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Matteo Ferro, Gennaro Musi, Michele Marchioni, Martina Maggi, Alessandro Veccia, Francesco Del Giudice, Biagio Barone, Felice Crocetto, Francesco Lasorsa, Alessandro Antonelli, Luigi Schips, Riccardo Autorino, Gian Maria Busetto, Daniela Terracciano, Giuseppe Lucarelli, Octavian Sabin Tataru
Summary: Renal cancer management poses challenges throughout the entire process from diagnosis to treatment and follow-up. The differentiation between benign and malignant tissues in cases of small renal masses and cystic lesions can be problematic, even with imaging or renal biopsy. Recent advances in artificial intelligence, imaging techniques, and genomics provide potential for helping clinicians with risk stratification, treatment selection, follow-up strategies, and prognosis. However, further prospective studies with larger patient cohorts are needed to validate previous results and implement these techniques into clinical practice.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Medicine, General & Internal
Alfredo Distante, Laura Marandino, Riccardo Bertolo, Alexandre Ingels, Nicola Pavan, Angela Pecoraro, Michele Marchioni, Umberto Carbonara, Selcuk Erdem, Daniele Amparore, Riccardo Campi, Eduard Roussel, Anna Calio, Zhenjie Wu, Carlotta Palumbo, Leonardo D. D. Borregales, Peter Mulders, Constantijn H. J. Muselaers
Summary: Renal cell carcinoma (RCC) presents histopathological challenges for accurate diagnosis and prognosis. This literature review explores recent advancements in AI applications in RCC pathology, with the aim of improving precision, efficiency, and objectivity in histopathological analysis. AI-powered approaches demonstrate effective identification and classification abilities, enabling accurate diagnosis, grading, and prognosis prediction. Challenges include standardization, generalizability, performance benchmarking, and data integration into clinical workflows. Accurate interpretation of AI decisions by pathologists and robust validation workflows are crucial for enhancing patient care.
Review
Urology & Nephrology
Pietro Diana, Tobias Klatte, Daniele Amparore, Riccardo Bertolo, Umberto Carbonara, Selcuk Erdem, Alexandre Ingels, Onder Kara, Laura Marandino, Michele Marchioni, Stijn Muselaers, Nicola Pavan, Angela Pecoraro, Alessio Pecoraro, Eduard Roussel, Riccardo Campi
Summary: This study systematically reviewed screening programs for renal cell carcinoma (RCC) and found a relative lack of studies reporting the efficacy and cost-effectiveness of RCC screening. Targeting high-risk individuals and combining RCC detection with other health checks may be pragmatic options to improve cost-effectiveness and reduce potential harms.
WORLD JOURNAL OF UROLOGY
(2023)
Review
Urology & Nephrology
Michele Marchioni, Daniele Amparore, Igino Andrea Magli, Riccardo Bertolo, Umberto Carbonara, Selcuk Erdem, Alexandre Ingels, Constantijn H. J. Muselaers, Onder Kara, Marco Mascitti, Tobias Klatte, Maximilian Kriegmair, Nicola Pavan, Eduard Roussel, Angela Pecoraro, Laura Marandino, Riccardo Campi, Luigi Schips
Summary: The role of lymph node dissection (LND) in patients with renal cell carcinoma undergoing surgery is still controversial. Current research suggests a possible survival benefit of LND in high-risk patients, but evidence from randomized clinical trials is still lacking. LND is currently mainly used for staging purposes.
ASIAN JOURNAL OF UROLOGY
(2022)
Article
Infectious Diseases
Claudio Ucciferri, Antonio Auricchio, Carmine Cutone, Alessandro Di Gasbarro, Jacopo Vecchiet, Katia Falasca
Summary: This study found that the mortality rate of infective endocarditis (IE) patients was associated with factors such as age, estimated glomerular filtration rate, procalcitonin values, cerebral embolization, and inadequate antibiotic therapy. Procalcitonin values at the diagnosis of IE and 48-72 hours after starting antibiotics can be used as prognostic factors for stratifying patient risk and setting up personalized treatment.
INFECTIOUS DISEASE REPORTS
(2022)